Skip to main content
NCBI home page
Cancer Science logoLink to Cancer Science
. 2005 Aug 19;95(4):316–320. doi: 10.1111/j.1349-7006.2004.tb03209.x

Tumor formation is correlated with expression of β‐catenin‐accumulated crypts in azoxymethane‐induced colon carcinogenesis in mice

Kazuya Hata 1,2, Yasuhiro Yamada 1, Toshiya Kuno 1, Yoshinobu Hirose 1, Akira Hara 1, Sheng Hong Qiang 1, Hideki Mori 1,✉
PMCID: PMC11158367  PMID: 15072589

Abstract

We have reported that β‐catenin‐accumulated crypts (BCAC) are independent of aberrant crypt foci (ACF) in the colonic mucosa of rats exposed to colorectal carcinogens, and we suggested that they may be premalignant lesions. In the present study, we performed a comparative study on the formation of the two types of early‐appearing lesions (BCAC and ACF), and tumors of the colon in two mouse strains with different susceptibility to azoxymethane (AOM). SWR/J mice are known to be relatively susceptible to AOM, whereas AKR/J mice are reported to be virtually resistant. Both AKR/J and SWR/J mice, 6 weeks old, received subcutaneous injections of AOM (15 mg/kg body weight) once a week for 3 weeks, and were sacrificed at 16 and 41 weeks of age. Colons of the animals sacrificed at 16 and 41 weeks of age were processed to examine expression of the early‐appearing lesions and neoplasms. Although AKR/J mice had a lower incidence of colonic tumors than SWR/J mice did, AKR/J mice showed a similar frequency of ACF to that in SWR/J mice. In both strains, ACF were detected at high frequency in the proximal colon, whereas tumors developed mainly in the distal colon. Importantly, the incidence of BCAC in SWR/J mice was significantly higher than that in AKR/J mice, and the highest frequency was observed in the distal segments of the colon. These results support the idea that BCAC are a reliable surrogate endpoint for colon carcinogenesis in mice.

Abbreviations:

BCAC

β‐catenin‐accumulated crypts

ACF

aberrant crypt foci

AOM

azoxymethane

APC

adenomatous polyposis coli

References

  • 1. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL. Genetic alterations during colorectal‐ tumor development. N Engl J Med 1988; 319: 525–32. [DOI] [PubMed] [Google Scholar]
  • 2. Bird RP, McLellan EA, Bruce WR. Aberrant crypts, putative precancerous lesions, in the study of the role of diet in the aetiology of colon cancer. Cancer Surv 1989; 8: 189–200. [PubMed] [Google Scholar]
  • 3. Bird RP. Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Lett 1987; 37: 147–51. [DOI] [PubMed] [Google Scholar]
  • 4. Bird RP. Role of aberrant crypt foci in understanding the pathogenesis of colon cancer. Cancer Lett 1995; 93: 55–71. [DOI] [PubMed] [Google Scholar]
  • 5. Yamada Y, Yoshimi N, Hirose Y, Kawabata K, Matsunaga K, Shimizu M, Hara A, Mori H. Frequent β‐catenin gene mutations and accumulations of the protein in the putative preneoplastic lesions lacking macroscopic aberrant crypt foci appearance, in rat colon carcinogenesis. Cancer Res 2000; 60: 3323–7. [PubMed] [Google Scholar]
  • 6. Yamada Y, Yoshimi N, Hirose Y, Matsunaga K, Katayama M, Sakata K, Shimizu M, Kuno T, Mori H. Sequential analysis of morphological and biological properties of β‐catenin‐accumulated crypts, provable premalignant lesions independent of aberrant crypt foci in rat colon carcinogenesis. Cancer Res 2001; 61: 1874–8. [PubMed] [Google Scholar]
  • 7. Yamada Y, Yoshimi N, Hirose Y, Hara A, Shimizu M, Kuno T, Katayama M, Qiao Z, Mori H. Suppression of occurrence and advancement of β‐catenin‐accumulated crypts, possible premalignant lesions of colon cancer, by selective cyclooxygenase‐2 inhibitor, celecoxib. Jpn J Cancer Res 2001; 92: 617–23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Yamada Y, Hata K, Hirose Y, Hara A, Sugie S, Kuno T, Yoshimi N, Tanaka T, Mori H. Microadenomatous lesions involving loss of Apc heterozygosity in the colon of adult Apc(Min/+) mice. Cancer Res 2002; 62: 6367–70. [PubMed] [Google Scholar]
  • 9. Paulsen JE, Steffensen IL, Loberg EM, Husoy T, Namork E, Alexander J. Qualitative and quantitative relationship between dysplastic aberrant crypt foci and tumorigenesis in the Min/+ mouse colon. Cancer Res 2001; 61: 5010–5. [PubMed] [Google Scholar]
  • 10. Kuno T, Yamada Y, Hirose Y, Katayama M, Sakata K, Hara A, Saji S, Mori H. Induction of apoptosis by sulindac in azoxymethane‐induced possible colonic premalignant lesions in rats. Jpn J Cancer Res 2002; 93: 242–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. β‐Catenin is a target for the ubiquitin‐proteasome pathway. EMBO J 1997; 16: 3797–804. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Pretlow TP, O'Riordan MA, Kolman MF, Jurcisek JA. Colonic aberrant crypts in azoxymethane‐treated F344 rats have decreased hexosaminidase activity. Am J Pathol 1990; 136: 13–6. [PMC free article] [PubMed] [Google Scholar]
  • 13. Yamada Y, Mori H. Precancerous lesions for colorectal cancers in rodents: a new concept. Carcinogenesis 2003; 24: 1015–9. [DOI] [PubMed] [Google Scholar]
  • 14. Papanikolaou A, Wang QS, Delker DA, Rosenberg DW. Azoxymethane‐induced colon tumors and aberrant crypt foci in mice of different genetic susceptibility. Cancer Lett 1998; 130: 29–34. [DOI] [PubMed] [Google Scholar]
  • 15. Papanikolaou A, Wang QS, Papanikolaou D, Whiteley HE, Rosenberg DW. Sequential and morphological analyses of aberrant crypt foci formation in mice of differing susceptibility to azoxymethane‐induced colon carcinogenesis. Carcinogenesis 2000; 21: 1567–72. [PubMed] [Google Scholar]
  • 16. Powell SM, Zilz N, Beazer‐Barclay Y, Bryan TM, Hamilton SR, Thibodeau SN, Vogelstein B, Kinzler KW. APC mutations occur early during colorectal tumorigenesis. Nature 1992; 359: 235–7. [DOI] [PubMed] [Google Scholar]
  • 17. Yamada Y, Oyama T, Hirose Y, Hara A, Sugie S, Yoshida K, Yoshimi N, Mori H. β‐Catenin mutation is selected during malignant transformation in colon carcinogenesis. Carcinogenesis 2003; 24: 91–7. [DOI] [PubMed] [Google Scholar]
  • 18. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW. Activation of β‐catenin‐Tcf signaling in colon cancer by mutations in β‐catenin or APC. Science 1997; 275: 1787–90. [DOI] [PubMed] [Google Scholar]
  • 19. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW. Identification of c‐MYC as a target of the APC pathway. Science 1998; 281: 1509–12. [DOI] [PubMed] [Google Scholar]
  • 20. Tetsu O, McCormick F. Beta‐catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999; 398: 422–6. [DOI] [PubMed] [Google Scholar]
  • 21. Takahashi M, Fukuda K, Sugimura T, Wakabayashi K. β‐catenin is frequently mutated and demonstrates altered cellular location in azoxymethane‐induced rat colon tumors. Cancer Res 1998; 58: 42–6. [PubMed] [Google Scholar]
  • 22. Takahashi M, Nakatsugi S, Sugimura T, Wakabayashi K. Frequent mutations of the β‐catenin gene in mouse colon tumors induced by azoxymethane. Carcinogenesis 2000; 21: 1117–20. [PubMed] [Google Scholar]
  • 23. Miyoshi Y, Nagase H, Ando H, Horii A, Ichii S, Nakatsuru S, Aoki T, Miki Y, Mori T, Nakamura Y. Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. Hum Mol Genet 1992; 1: 229–33. [DOI] [PubMed] [Google Scholar]
  • 24. Reddy BS, Rao CV, Seibert K. Evaluation of cyclooxygenase‐2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res 1996; 56: 4566–9. [PubMed] [Google Scholar]
  • 25. Zheng Y, Kramer PM, Lubet RA, Steele VE, Kelloff GJ, Pereira MA. Effect of retinoids on AOM‐induced colon cancer in rats: modulation of cell proliferation, apoptosis and aberrant crypt foci. Carcinogenesis 1999; 20: 255–60. [DOI] [PubMed] [Google Scholar]
  • 26. Rao CV, Wang CX, Simi B, Lubet R, Kelloff G, Steele V, Reddy BS. Enhancement of experimental colon cancer by genistein. Cancer Res 1997; 57: 3717–22. [PubMed] [Google Scholar]
  • 27. Hirose Y, Kuno T, Yamada Y, Sakata K, Katayama M, Yoshida K, Qiao Z, Hata K, Yoshimi N, Mori H. Azoxymethane‐induced beta‐catenin‐accumulated crypts in colonic mucosa of rodents as an intermediate biomarker for colon carcinogenesis. Carcinogenesis 2003; 24: 107–11. [DOI] [PubMed] [Google Scholar]
  • 28. Takayama T, Katsuki S, Takahashi Y, Ohi M, Nojiri S, Sakamaki S, Kato J, Kogawa K, Miyake H, Niitsu Y. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med 1998; 339: 1277–84. [DOI] [PubMed] [Google Scholar]
  • 29. Takahashi M, Mutoh M, Kawamori T, Sugimura T, Wakabayashi K. Altered expression of β‐catenin, inducible nitric oxide synthase and cyclooxygenase‐2 in azoxymethane‐induced rat colon carcinogenesis. Carcinogenesis 2000; 21: 1319–27. [PubMed] [Google Scholar]
  • 30. Ochiai M, Ushigome M, Fujiwara K, Ubegai T, Kawamori T, Sugimura T, Nagao M, Nakagama H. Characterization of dysplastic aberrant crypt foci in the rat colon induced by 2‐amino‐1‐methyl‐6‐phenylimidazo[4,5‐b]pyridine. Am J Pathol 2003; 163: 1607–14. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Cancer Science are provided here courtesy of Wiley

RESOURCES